Out of proportion pulmonary hypertension in obstructive lung diseases

被引:10
作者
Chatterjee, Kshitij [1 ]
Tarawneh, Ahmad R. [2 ]
Alam, Shoaib [2 ]
机构
[1] Univ Arkansas Med Sci, Dept Med, Little Rock, AR 72205 USA
[2] Univ Arkansas Med Sci, Dept Med, Div Pulm Crit Care Med & Sleep Med, Little Rock, AR 72205 USA
关键词
chronic obstructive pulmonary disease; chronic obstructive pulmonary disease-pulmonary hypertension; obstructive lung disease; out of proportion; pulmonary hypertension; HEART-FAILURE; CONTROLLED-TRIAL; ARTERIAL-HYPERTENSION; CYSTIC-FIBROSIS; OXYGEN-THERAPY; COPD; EMPHYSEMA; BOSENTAN; SURVIVAL; EXERCISE;
D O I
10.1097/MCP.0000000000000457
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Purpose of review Pulmonary hypertension is common (25-90%) in chronic obstructive pulmonary diseases (COPDs). Severe pulmonary hypertension, however, is quite rare (1-3%). The term 'out of proportion' pulmonary hypertension is still widely used. New guidelines instead propose to use the term 'Severe pulmonary hypertension' if mean pulmonary arterial pressure at least 35 mmHg or cardiac index (CI) is less than 2.0 l/min/m(2) on right heart catheterization (RHC). Why only a minority of COPD patients develop severe pulmonary hypertension is unclear. Recent findings When present, severe pulmonary hypertension in COPD is associated with increased dyspnea and decreased survival and often does not closely correlate with degree of obstructive abnormality on pulmonary function testing. COPD patients with severe pulmonary hypertension experience circulatory limitation at maximum exercise, and not ventilatory limitation, which is typical for moderate-to-severe COPD patients with no or moderate pulmonary hypertension. Summary There is no conclusive evidence to support or completely reject the possibility of the use of specific pulmonary arterial hypertension (PAH) therapies in pulmonary hypertension associated with COPD. In mild-to-moderate COPD patients who have severe and progressive symptoms, and have evidence of severe pulmonary hypertension on RHC, specific PAH therapies may be used similar to WHO group-I PAH guidelines.
引用
收藏
页码:161 / 172
页数:12
相关论文
共 54 条
[1]   Standard therapies for pulmonary arterial hypertension [J].
Alam, Shoaib ;
Palevsky, Harold I. .
CLINICS IN CHEST MEDICINE, 2007, 28 (01) :91-+
[2]  
[Anonymous], 1980, ANN INTERN MED, V93, P391
[3]  
[Anonymous], FRONT PHYSL
[4]   Pulmonary hypertension in chronic obstructive pulmonary disease [J].
Barberà, JA ;
Peinado, VI ;
Santos, S .
EUROPEAN RESPIRATORY JOURNAL, 2003, 21 (05) :892-905
[5]   Worsening of pulmonary gas exchange with nitric oxide inhalation in chronic obstructive pulmonary disease [J].
Barbera, JA ;
Roger, N ;
Roca, J ;
Rovira, I ;
Higenbottam, TW ;
RodriguezRoisin, R .
LANCET, 1996, 347 (8999) :436-440
[6]   Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial [J].
Blanco, Isabel ;
Santos, Salud ;
Gea, Joaqim ;
Gueell, Rosa ;
Torres, Ferran ;
Gimeno-Santos, Elena ;
Rodriguez, Diego A. ;
Vilaro, Jordi ;
Gomez, Begona ;
Roca, Josep ;
Albert Barbera, Joan .
EUROPEAN RESPIRATORY JOURNAL, 2013, 42 (04) :982-992
[7]   Ventilatory and Cardiocirculatory Exercise Profiles in COPD The Role of Pulmonary Hypertension [J].
Boerrigter, Bart G. ;
Bogaard, Harm J. ;
Trip, Pia ;
Groepenhoff, Herman ;
Rietema, Heleen ;
Holverda, Sebastiaan ;
Boonstra, Anco ;
Postmus, Pieter E. ;
Westerhof, Nico ;
Vonk-Noordegraaf, Anton .
CHEST, 2012, 142 (05) :1166-1174
[9]   PATTERNS OF CARDIOVASCULAR DYSFUNCTION IN CHRONIC OBSTRUCTIVE LUNG-DISEASE [J].
BURROWS, B ;
RABINOWITZ, M ;
KETTEL, LJ ;
DIENER, CF ;
NIDEN, AH .
NEW ENGLAND JOURNAL OF MEDICINE, 1972, 286 (17) :912-+
[10]   A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST) [J].
Califf, RM ;
Adams, KF ;
McKenna, WJ ;
Gheorghiade, M ;
Uretsky, BF ;
McNulty, SE ;
Darius, H ;
Schulman, K ;
Zannad, F ;
HandbergThurmond, E ;
Harrell, FE ;
Wheeler, W ;
SolerSoler, J ;
Swedberg, K .
AMERICAN HEART JOURNAL, 1997, 134 (01) :44-54